Lanoteplase
Title: Lanoteplase
CAS Registry Number: 171870-23-8
CAS Name: N-[N2-(N-Glycyl-L-alanyl)-L-arginyl]-117-L-glutamine-245-L-methionine-(1-5)-(87-527)-plasminogen activator (human tissue-type protein moiety)
Manufacturers' Codes: BMS-200980; SUN-9216
Literature References: Genetically engineered variant of human tissue plasminogen activator (t-PA); expressed in mammalian cells. mol wt ~50 kDa. Derived by deletion of the fibronectin-like and EGF-like domains and mutation of glutamine for asparagine at position 117. Prepn: G. R. Larsen, T. J. Ahern, WO 8704722; G. R. Larsen, US 5002887 (1987, 1991 both to Genetics Inst.). Thrombolytic efficacy in rats: K. Umemura et al., Eur. J. Pharmacol. 262, 27 (1994). Clinical comparison with alteplase in myocardial infarction: P. den Heijer et al., Circulation 98, 2117 (1998). Review of pharmacology and clinical development: J. Llevadot, R. P. Giugliano, Expert Opin. Invest. Drugs 9, 2689-2694 (2000).
Therap-Cat: Thrombolytic.
Keywords: Thrombolytic.
 
 
Status: This monograph has been retired and is no longer subject to revision or update.

Others monographs:
Ciliary Neurotrophic FactorNeotameRivastigmineSodium Folate
TralomethrinCiafosEleutherobinMercuric Cyanide
Carbarsone5-Nitrosalicylic AcidStar Aniseo-Iodobenzoic Acid
GelatinFerric ChlorideDimethyl-p-phenylenediamineNicomorphine
©2016 DrugLead US FDA&EMEA